[A15-47] Alirocumab - Benefit assessment according to §35a Social Code Book V
Last updated 15.02.2016
Project no.:
A15-47
Commission:
Commission awarded on 02.11.2015 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-74 | Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
| A16-16 | Alirocumab - Addendum to Commission A15-47 | Commission completed |
| A23-136 | Alirocumab (hypercholesterolaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2016-05-04 A G-BA decision was published.